Sign in

CIK 0001662774

  • Non-accelerated filer
  • Smaller reporting company

IRulya Therapeutics Inc.

Sign in to watch
Ticker
IRLA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
901024039
Phone
+1 203-208-8994
Business address
101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
Former names
Quince Therapeutics, Inc., Cortexyme, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Exercise or conversion Chief Executive Officer acquired 60,000 shares (option exercise)
  6. 4 Exercise or conversion COO & Chief Financial Officer acquired 30,000 shares (option exercise)
  7. 4 Open-market buy Chief Scientific Officer bought 763 shares at $14.40 ($10,987)
  8. 4 Open-market sale Director sold 1,000 shares at $88.93 ($88,930)
  9. 4 Open-market sale COO & Chief Financial Officer sold 4,963 shares at $98.50 ($488,856)
  10. 4 Open-market sale Director sold 6,000 shares at an average $95.44 ($572,644)
  11. 4 Open-market sale COO & Chief Financial Officer sold 22,000 shares at an average $95.31 ($2,096,779)
  12. 4 Open-market sale Chief Medical Officer sold 10,000 shares at $100.00 ($1,000,000)
  13. 4 Open-market sale Chief Medical Officer sold 58,261 shares at an average $54.04 ($3,148,172)
  14. 4 Open-market sale COO & Chief Financial Officer sold 20,000 shares at an average $54.15 ($1,083,074)
  15. 4 Open-market sale Director sold 550 shares at an average $55.15 ($30,333)
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Open-market sale Chief Executive Officer sold 30,000 shares at an average $34.58 ($1,037,361)

Page 7 of 11 · 211 filings